AmpiMed Corp., a Tucson, Ariz.-based oncology drug startup, has secured $5 million of a $22 million Series C round, according to a regulatory filing. Backers include BioMed Venture Partners, Biotech Insight Ventures, Solstice Capital and Valley Ventures. www.amplimed.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.